YOLFTbeta
74

Great Novel Therapeutics Biotech & Medicals

7427 · TWO · Healthcare / Biotechnology

58.00TWD-0.60 (-1.02%)

Price History

Full chart

Market Stats

Previous Close58.60
Open59.60
Day Range57.60 – 59.60
52-Week Range29.25 – 82.80
Volume174.86K
Market Cap3.72B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.27
Dividend Yield0.00%
Beta0.21
50-Day Avg71.52
200-Day Avg46.60

About

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan. The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity. It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Chia-Nan Chen
  • Employees23
  • HeadquartersNo.508, Zhongxiao East Road, Taipei, Taiwan, 115, Taiwan
  • Websitehttps://www.gntbm.com.tw

Leadership

  • Dr. Chia-Nan ChenPresident & Chairman of the Board
  • Ms. Yi-Hua WuFinancial & Accounting Manager
  • Ms. Pei-Ching HsuDirector of Administration Department
  • Mr. Jia Xiong ChenAssistant Director of New Drug R&D Center and Director

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--630.00K540.00K4.85M1.69M1.21M
Growth (%)----14.29%+798.15%-65.26%-28.49%
Cost of Revenue-939.00K347.00K76.00K43.00K670.00K2.39M
Gross Profit--939.00K283.00K464.00K4.81M1.01M-1.18M
Gross Margin--44.92%85.93%99.11%60.24%-98.26%
Operating Expense-42.00M36.80M57.90M70.63M113.66M98.36M
Operating Income--42.94M-36.52M-57.44M-65.82M-112.65M-99.54M
Operating Margin---5796.98%-10636.67%-1357.11%-6685.28%-8260.91%
EBITDA-28.89M-43.36M-35.08M-53.96M-54.91M-97.86M-89.69M
EBITDA Margin---5568.10%-9992.04%-1132.27%-5807.83%-7443.32%
Net Income-29.88M-31.27M-35.86M-55.78M-61.54M-104.92M-97.47M
Net Income Margin---5691.59%-10329.44%-1268.87%-6226.94%-8089.05%
R&D-19.47M19.11M38.53M53.13M85.09M72.02M
R&D as % of Total Revenue--3032.86%7135.74%1095.40%5049.85%5976.35%
Interest Expense-21.00K0091.00K125.00K97.00K
Interest Expense % of Total Revenue--0.00%0.00%1.88%7.42%8.05%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets85.67M125.85M229.96M372.85M644.85M662.60M526.75M
Total Liabilities18.67M5.30M21.61M12.05M26.81M29.28M23.77M
Total Equity67.00M120.55M208.35M360.80M618.04M633.32M502.98M
Cash24.88M67.02M62.79M111.08M179.55M155.06M29.84M
Total Debt-76.00K860.00K833.00K14.38M10.46M-
Net Debt-24.88M-66.95M-61.93M-110.25M-165.18M-144.59M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-18.51M-41.88M-33.92M-65.81M-54.99M-76.85M-87.56M
Investing Cash Flow-30.90M430.00K-90.32M-89.21M-182.78M-133.49M-
Financing Cash Flow27.68M83.60M120.00M203.31M306.24M185.84M-
Capital Expenditure013.07M28.00M12.57M2.92M3.46M3.49M
Free Cash Flow-18.51M-54.95M-61.92M-78.39M-57.92M-80.31M-91.05M
FCF to OCF100.00%131.21%182.56%119.10%105.32%104.51%103.99%

Key Statistics & Ratios

Market Cap3.72B
Enterprise Value3.09B
Trailing P/E0.00
Forward P/E0.00
Price / Sales599.21
Price / Book5.02
EPS-2.27
Book Value14.24
Revenue (TTM)6.21M
Gross Profit (TTM)1.16M
EBITDA-113.22M
Profit Margin0.00%
Operating Margin-1091.75%
Return on Equity-16.95%
Return on Assets-10.68%
Shares Outstanding52.91M
Shares Float45.42M
Beta0.21
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%